A Randomized Phase Ii Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (cml) Patients in Complete Hematological Remission after Imatinib Induction Therapy.
